Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Trypanosoma brucei gambiense | vacuolar-type proton translocating pyrophosphatase 1, putative | References | |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 727 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
ED50 (functional) | = 727 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
IC50 (binding) | = 16.7 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
IC50 (binding) | = 16.7 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
IC50 (functional) | = 47.9 uM | In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) | ChEMBL. | 15857119 |
IC50 (functional) | = 47.9 uM | In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) | ChEMBL. | 15857119 |
IC50 (functional) | = 110 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
Log IC50 (functional) | = 3.96 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
TI (functional) | = 44 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
TI (functional) | = 44 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
3 literature references were collected for this gene.